Amphiregulin:: A new growth factor in hepatocarcinogenesis

被引：67

作者：

Berasain, C. ^{[1
]}

Castillo, J. ^{[1
]}

Perugorria, M. J. ^{[1
]}

Prieto, J. ^{[1
]}

Avila, M. A. ^{[1
]}

机构：

[1] Univ Navarra, CIMA, Div Hepatol & Gene Therapy, Pamplona 31008, Spain

来源：

CANCER LETTERS | 2007年 / 254卷 / 01期

关键词：

amphiregulin; proliferation; liver injury; cirrhosis; hepatocarcinoma; carcinogenesis; ALPHA-CONVERTING-ENZYME; RECEPTOR TYROSINE KINASE; WILMS-TUMOR SUPPRESSOR; CELL LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; EGF RECEPTOR; LIVER-REGENERATION; DISTINCT ROLES; RAT-LIVER; HB-EGF;

D O I：

10.1016/j.canlet.2007.01.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Amphiregulin (AR) is a member of the epidermal growth factor family and a ligand of the epidermal growth factor receptor (EGFR). As other ligands of the EGFR, AR is synthesized as a precursor that is shed from the plasma membrane by metalloproteases. Hyperactive autocrine loops involving AR production have been described in a variety of tumors, and this growth factor is thought to play a non-redundant role in cancer development. AR expression is not detected in the normal liver, however it is readily induced during acute liver injury and behaves as a potent pro-regenerative and survival factor. Increased AR expression is also detected in human chronic liver injury (liver cirrhosis), which is considered a pre-neoplastic condition. Recent evidences suggest that AR can play a unique role in liver tumorigenesis and in the maintenance of the neoplastic phenotype of hepatocarcinoma cells. In this review, we summarize some aspects of AR patho-biology and the rationale behind its definition as a novel target in hepatocarcinoma therapy. (c) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：30 / 41

页数：12

共 87 条

[31] Blockade of IGF-1 receptor tyrosine kinase has antlineoplastic effects in hepatocellular carcinoma cells [J].